Skip to main content

Main menu

  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us

Clinical Medicine Journal

  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

User menu

  • Log in

Search

  • Advanced search
RCP Journals
Home
  • Log in
  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us
Advanced

Clinical Medicine Journal

clinmedicine Logo
  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

Research in brief: Colchicine for chronic coronary disease: a recent randomised controlled trial

Rajan S Pooni and Tevfik F Ismail
Download PDF
DOI: https://doi.org/10.7861/clinmed.2020-0981
Clin Med January 2021
Rajan S Pooni
ASt Bartholomew's Hospital, London, UK
Roles: internal medicine trainee
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tevfik F Ismail
BKing's College London, London, UK and consultant cardiologist, Guy's and St Thomas' NHS Foundation Trust, London, UK
Roles: clinical senior lecturer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Background

Summary of Nidorf SM, Fiolet ATL, Mosterd A et al. Colchicine in patients with chronic coronary disease. N Engl J Med 2020;383:1838–47.1

Atherosclerosis and its sequelae remain the leading cause of cardiovascular-related mortality worldwide.2–4 A combination of genetic and acquired risk factors contribute to an inflammatory milieu that leads to atherosclerotic plaque formation and ultimately plaque rupture.5,6 Given the central role of inflammation in this process, recent efforts to improve outcomes for patients with coronary disease have focused on targeting inflammatory pathways.

The selective IL-1β inhibitor, canakinumab, has been shown to reduce cardiovascular events among high-risk patients with a history of myocardial infarction (MI) and elevated high-sensitivity C-reactive protein.7 Similarly, low-dose colchicine, an agent with a broader spectrum of anti-inflammatory properties, has also shown benefit in post-infarct patients.8,9 However, the impact of such an approach in patients with otherwise stable chronic coronary disease was hitherto unknown. Here, we review a recent multi-centre randomised controlled trial (LoDoCo2) evaluating the efficacy of low-dose colchicine in this population.1

Study review

Following an initial open-label phase in which all 6,528 patients enrolled in the study received low-dose colchicine (500 μg daily), a total of 5,522 patients underwent randomisation; 2,762 were assigned to the colchicine group and 2,760 to the placebo group. Key inclusion criteria included established coronary disease diagnosed either on invasive coronary angiography or computed tomography coronary angiography (coronary artery calcium ≥400 HU), and clinical stability for at least 6 months prior to enrolment. This contrasts with previous studies utilising colchicine that recruited patients within 30 days of an acute MI or were open-label/non-blinded throughout.7,8 However, a large number of patients in LoDoCo2 had been subjected to coronary angiography because of previous acute coronary syndromes (84%), albeit at least 6 months prior to enrolment.

The primary endpoint was a composite of cardiovascular outcomes including cardiovascular mortality, MI, ischaemic stroke and unplanned coronary intervention. The median duration of follow-up across both groups was 28.6 months. The primary endpoint was reached by 6.8% of patients in the intervention group compared to 9.6% in the control group (intention-to-treat analysis, number needed to treat ∼36).

Despite the observation of a statistically significant benefit of colchicine when compared with placebo, there are several study limitations to consider. During the initial open-label phase, a significant proportion of patients (15.7%) dropped out prior to subsequent randomisation, shifting the paradigm from intention-to-treat towards as-treated analysis by excluding a proportion of suitable patients who could not tolerate the therapy prior to formal data interpretation. Furthermore, this phase confounds the results of the study through administration of colchicine to all patients prior to randomisation. Of note however, after randomisation, the premature discontinuation rate was exactly 10.5% in both treatment and placebo arms.

Although the study was powered to detect a 30% reduction in events with colchicine, the actual definition of the primary endpoint was changed several times during the study, presumably to ensure that an adequate number of events were accrued. Furthermore, with 84% of patients having a prior history of acute coronary syndrome at least 6 months prior to enrolment, and the event rate being driven by ischaemia-related revascularisation, the magnitude of benefit in lower risk populations remains unclear. Finally, a higher, albeit non-significant, incidence of non-cardiovascular-related mortality was observed in the colchicine group. This merits further investigation.

  • © Royal College of Physicians 2021. All rights reserved.

References

  1. ↵
    1. Nidorf SM
    , Fiolet ATL, Mosterd A, et al. Colchicine in patients with chronic coronary disease. N Engl J Med 2020;383:1838–47.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Herrington W
    , Lacey B, Sherliker P, Armitage J, Lewington S. Epidemiology of atherosclerosis and the potential to reduce the global burden of atherothrombotic disease. Circ Res 2016;118:535–46.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Khan MA
    , Hashim MJ, Mustafa H, et al. Global epidemiology of ischemic heart disease: Results from the global burden of disease study. Cureus 2020;12:e9349.
    OpenUrl
  4. ↵
    1. Roth GA
    , Johnson C, Abajobir A, et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol 2017;70:1–25.
    OpenUrlFREE Full Text
  5. ↵
    1. Libby P
    , Loscalzo J, Ridker PM, et al. Inflammation, immunity, and infection in atherothrombosis: JACC review topic of the week. J Am Coll Cardiol 2018;72:2071–81.
    OpenUrlFREE Full Text
  6. ↵
    1. Libby P
    , Okamoto Y, Rocha VZ, Folco E. Inflammation in atherosclerosis: transition from theory to practice. Circ J 2010;74:213–20.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Ridker PM
    , Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017;377:1119–31.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Nidorf SM
    , Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol 2013;61:404–10.
    OpenUrlFREE Full Text
  9. ↵
    1. Tardif JC
    , Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med 2019;381:2497–505.
    OpenUrlCrossRefPubMed
Back to top
Previous articleNext article

Article Tools

Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Research in brief: Colchicine for chronic coronary disease: a recent randomised controlled trial
Rajan S Pooni, Tevfik F Ismail
Clinical Medicine Jan 2021, 21 (1) e1; DOI: 10.7861/clinmed.2020-0981

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research in brief: Colchicine for chronic coronary disease: a recent randomised controlled trial
Rajan S Pooni, Tevfik F Ismail
Clinical Medicine Jan 2021, 21 (1) e1; DOI: 10.7861/clinmed.2020-0981
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Background
    • Study review
    • References
  • Info & Metrics

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Research in brief: Empagliflozin for patients with heart failure and preserved ejection fraction
  • Research in brief: Effective pharmacotherapy for the management of obesity
Show more Research in brief

Similar Articles

FAQs

  • Difficulty logging in.

There is currently no login required to access the journals. Please go to the home page and simply click on the edition that you wish to read. If you are still unable to access the content you require, please let us know through the 'Contact us' page.

  • Can't find the CME questionnaire.

The read-only self-assessment questionnaire (SAQ) can be found after the CME section in each edition of Clinical Medicine. RCP members and fellows (using their login details for the main RCP website) are able to access the full SAQ with answers and are awarded 2 CPD points upon successful (8/10) completion from:  https://cme.rcplondon.ac.uk

Navigate this Journal

  • Journal Home
  • Current Issue
  • Ahead of Print
  • Archive

Related Links

  • ClinMed - Home
  • FHJ - Home
clinmedicine Footer Logo
  • Home
  • Journals
  • Contact us
  • Advertise
HighWire Press, Inc.

Follow Us:

  • Follow HighWire Origins on Twitter
  • Visit HighWire Origins on Facebook

Copyright © 2021 by the Royal College of Physicians